Skip to main content
Top
Published in: International Urology and Nephrology 8/2014

01-08-2014 | Urology - Original Paper

Sentinel lymph node dissection combined with meticulous histology increases the detection rate of nodal metastases in prostate cancer

Authors: Michal Staník, Ivo Čapák, Daniel Macík, Jiří Vašina, Eva Lžičařová, Jiří Jarkovský, Martin Šustr, David Miklánek, Jan Doležel

Published in: International Urology and Nephrology | Issue 8/2014

Login to get access

Abstract

Purpose

To evaluate benefits of sentinel lymph node (SLN) biopsy for staging accuracy in prostate cancer. Extended pelvic lymph node dissection (ePLND) is a preferred staging tool; however, it may underestimate the incidence of nodal involvement.

Methods

Eighty patients with estimated risk of lymphadenopathy above 5 % based on Briganti nomogram had Tc-99m-labeled nanocolloid injected into the prostate. Planar lymphoscintigraphy and single-photon emission computed tomography/CT were performed to localize SLNs. Radioguided SLN dissection was followed by backup ePLND comprising external iliac, obturator and internal iliac regions. All SLNs were serially sectioned every 150 μm and examined using hematoxylin and eosin; immunohistochemical staining was applied every 300 μm.

Results

A total of 335 SLNs were detected, and 17 % were located outside ePLND template. Nodal metastases were diagnosed in 32 patients (40 %). Without radioguided SLN localization, solitary metastases posteriorly to the branches of the internal ilaic vessels, in pararectal and common iliac regions would not have been removed in five of 32 patients (16 %). Using standard histology protocol, we would have diagnosed metastases in 23 patients with median size of 2.8 mm. Serial sectioning of SLN and immunohistochemistry led to the detection of metastases in additional nine patients (28 %) with median size of 0.2 mm.

Conclusion

ePLND comprised 83 % of SLNs, at least one SLN laid outside its template in 28 % of patients. ePLND and SLN dissection combined with nodal serial sectioning and immunohistochemistry increased the detection rate of nodal metastases by 68 % in comparison with ePLND alone and standard histology protocol.
Literature
1.
go back to reference Cheng L, Zincke H, Blute ML et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66–73PubMedCrossRef Cheng L, Zincke H, Blute ML et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66–73PubMedCrossRef
2.
go back to reference Heidenreich A, Bellmunt J, Bolla M et al (2011) European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 59:61–71PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M et al (2011) European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 59:61–71PubMedCrossRef
3.
go back to reference Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265PubMedCrossRef Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265PubMedCrossRef
4.
go back to reference Abdollah F, Sun M, Thuret R et al (2010) Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol 58:882–892PubMedCrossRef Abdollah F, Sun M, Thuret R et al (2010) Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer. Eur Urol 58:882–892PubMedCrossRef
5.
go back to reference Wawroschek F, Wagner T, Hamm M et al (2003) The influence of serial sections, immunohistochemistry and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132–137PubMedCrossRef Wawroschek F, Wagner T, Hamm M et al (2003) The influence of serial sections, immunohistochemistry and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132–137PubMedCrossRef
6.
go back to reference Briganti A, Karakiewicz PI, Chun FK et al (2007) Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 51:1573–1581PubMedCrossRef Briganti A, Karakiewicz PI, Chun FK et al (2007) Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 51:1573–1581PubMedCrossRef
7.
go back to reference Holl G, Dorn R, Wengenmair H et al (2009) Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 36:1377–1382PubMedCrossRef Holl G, Dorn R, Wengenmair H et al (2009) Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients. Eur J Nucl Med Mol Imaging 36:1377–1382PubMedCrossRef
8.
go back to reference Jeschke S, Beri A, Grüll M et al (2008) Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer. Eur Urol 58:126–133CrossRef Jeschke S, Beri A, Grüll M et al (2008) Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer. Eur Urol 58:126–133CrossRef
9.
go back to reference Joniau S, Van den Bergh L, Lerut E et al (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63:450–458PubMedCrossRef Joniau S, Van den Bergh L, Lerut E et al (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63:450–458PubMedCrossRef
10.
go back to reference Rousseau C, Rousseau T, Bridji B et al (2012) Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. Eur J Nucl Med Mol Imaging 39:291–299PubMedCrossRef Rousseau C, Rousseau T, Bridji B et al (2012) Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. Eur J Nucl Med Mol Imaging 39:291–299PubMedCrossRef
11.
go back to reference Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54:344–352PubMedCrossRef Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54:344–352PubMedCrossRef
12.
go back to reference Mattei A, Fuechsel FG, Bhatta Dhar N et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125PubMedCrossRef Mattei A, Fuechsel FG, Bhatta Dhar N et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125PubMedCrossRef
13.
go back to reference Van der Poel HG, Buckle T, Brouwer OR et al (2011) Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 60:826–833PubMedCrossRef Van der Poel HG, Buckle T, Brouwer OR et al (2011) Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 60:826–833PubMedCrossRef
14.
go back to reference Jeschke S, Lusuardi L, Myatt A et al (2012) Visualisation of the lymph node pathway in real time by laparoscopic radioisotope and fluorescence-guided sentinel lymph node dissection in prostate cancer staging. Urology 80:1080–1087PubMedCrossRef Jeschke S, Lusuardi L, Myatt A et al (2012) Visualisation of the lymph node pathway in real time by laparoscopic radioisotope and fluorescence-guided sentinel lymph node dissection in prostate cancer staging. Urology 80:1080–1087PubMedCrossRef
15.
go back to reference Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686PubMedCrossRef Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686PubMedCrossRef
16.
go back to reference Golimbu M, Morales P, Al-Askari S et al (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617–620PubMed Golimbu M, Morales P, Al-Askari S et al (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617–620PubMed
17.
go back to reference Fukuda M, Egawa M, Imao T et al (2007) Detection of sentinel node micrometastasis by step section and immunohistochemistry in patients with prostate cancer. J Urol 177:1313–1317PubMedCrossRef Fukuda M, Egawa M, Imao T et al (2007) Detection of sentinel node micrometastasis by step section and immunohistochemistry in patients with prostate cancer. J Urol 177:1313–1317PubMedCrossRef
18.
go back to reference Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487PubMedCrossRef Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61:480–487PubMedCrossRef
19.
go back to reference De Boer M, van Deurzen CH, van Dijck JA et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663PubMedCrossRef De Boer M, van Deurzen CH, van Dijck JA et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663PubMedCrossRef
20.
go back to reference Pagliarulo V, Hawes D, Brands FH et al (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735–2742PubMedCrossRef Pagliarulo V, Hawes D, Brands FH et al (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735–2742PubMedCrossRef
Metadata
Title
Sentinel lymph node dissection combined with meticulous histology increases the detection rate of nodal metastases in prostate cancer
Authors
Michal Staník
Ivo Čapák
Daniel Macík
Jiří Vašina
Eva Lžičařová
Jiří Jarkovský
Martin Šustr
David Miklánek
Jan Doležel
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0704-3

Other articles of this Issue 8/2014

International Urology and Nephrology 8/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.